Skip to Content
MilliporeSigma
Get up to 22% off for Pi Day until 3/26.Save Now
  • Regulation of a Notch3-Hes1 pathway and protective effect by a tocopherol-omega alkanol chain derivative in muscle atrophy.

Regulation of a Notch3-Hes1 pathway and protective effect by a tocopherol-omega alkanol chain derivative in muscle atrophy.

The Journal of pharmacology and experimental therapeutics (2014-10-19)
Yannick von Grabowiecki, Cynthia Licona, Lavinia Palamiuc, Paula Abreu, Vania Vidimar, Djalil Coowar, Georg Mellitzer, Christian Gaiddon
ABSTRACT

Muscular atrophy, a physiopathologic process associated with severe human diseases such as amyotrophic lateral sclerosis (ALS) or cancer, has been linked to reactive oxygen species (ROS) production. The Notch pathway plays a role in muscle development and in muscle regeneration upon physical injury. In this study, we explored the possibility that the Notch pathway participates in the ROS-related muscular atrophy occurring in cancer-associated cachexia and ALS. We also tested whether hybrid compounds of tocopherol, harboring antioxidant activity, and the omega-alkanol chain, presenting cytoprotective activity, might reduce muscle atrophy and impact the Notch pathway. We identified one tocopherol-omega alkanol chain derivative, AGT251, protecting myoblastic cells against known cytotoxic agents. We showed that this compound presenting antioxidant activity counteracts the induction of the Notch pathway by cytotoxic stress, leading to a decrease of Notch1 and Notch3 expression. At the functional level, these regulations correlated with a repression of the Notch target gene Hes1 and the atrophy/remodeling gene MuRF1. Importantly, we also observed an induction of Notch3 and Hes1 expression in two murine models of muscle atrophy: a doxorubicin-induced cachexia model and an ALS murine model expressing mutated superoxide dismutase 1. In both models, the induction of Notch3 and Hes1 were partially opposed by AGT251, which correlated with ameliorations in body and muscle weight, reduction of muscular atrophy markers, and improved survival. Altogether, we identified a compound of the tocopherol family that protects against muscle atrophy in various models, possibly through the regulation of the Notch pathway.

MATERIALS
Product Number
Brand
Product Description

USP
Doxorubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
USP
Transplatin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Tocopherols, mixed, FCC, Low-α type, FG
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥97.5% (HPLC)
Sigma-Aldrich
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, 98%
Sigma-Aldrich
Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)
Sigma-Aldrich
cis-Diamineplatinum(II) dichloride, ≥99.9% trace metals basis
Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard
USP
Menadione, United States Pharmacopeia (USP) Reference Standard
Menadione, European Pharmacopoeia (EP) Reference Standard
Cisplatin, European Pharmacopoeia (EP) Reference Standard
Supelco
Menadione, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Menadione (K3), analytical standard
Sigma-Aldrich
Menadione, crystalline
Sigma-Aldrich
Menadione, meets USP testing specifications
Sigma-Aldrich
cis-Diammineplatinum(II) dichloride, crystalline
Sigma-Aldrich
trans-Platinum(II)diammine dichloride